Prospective, randomized, controlled trial of silicate-substituted calcium phosphate versus rhBMP-2 in a minimally invasive transforaminal lumbar interbody fusion

Spine

Volumn 39, Issue 3, 2014, Pages 185-191

  Nandyala, Sreeharsha V ^a   Marquez Lara, Alejandro ^a   Fineberg, Steven J ^a   Pelton, Miguel ^a   Singh, Kern ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Actifuse; arthrodesis; ceramics; MIS TLIF; pseudarthrosis; rhBMP 2

Indexed keywords

ADULT; AGED; AGED, 80 AND OVER; BONE MORPHOGENETIC PROTEIN 2; CALCIUM COMPOUNDS; CALCIUM PHOSPHATES; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; SILICATES; SPINAL FUSION; SURGICAL PROCEDURES, MINIMALLY INVASIVE; TRANSFORMING GROWTH FACTOR BETA;

EID: 84894045351     PISSN: 03622436     EISSN: 15281159     Source Type: Journal    
DOI: 10.1097/BRS.0000000000000106     Document Type: Article

References (25)

1. Cahill KS, Chi JH, Day A, et al. Prevalence, complications, and hospital charges associated with use of bone-morphogenetic proteins in spinal fusion procedures. JAMA 2009; 302: 58-66.
2. Zimmermann G, Moghaddam A. Allograft bone matrix versus synthetic bone graft substitutes. Injury 2011; 42: S16-21.
3. Miyazaki M, Tsumura H, Wang JC, et al. An update on bone substitutes for spinal fusion. Eur Spine J 2009; 18: 783-99.
4. Lee YP, Ghofrani H. Bone graft substitutes and extenders. Contemp Spine Surg 2009; 10: 8.
5. Vaz K, Verma K, Protopsaltis T, et al. Bone grafting options for lumbar spine surgery: a review examining clinical effi cacy and complications. SAS J 2010; 4: 75-86.
6. Hofstetter C, Hartle R. Fundamentals of Operative Techniques in Neurosurgery. New York: Thieme; 2010: 883.
7. Seebach C, Schultheiss J, Wilhelm K, et al. Comparison of six bonegraft substitutes regarding to cell seeding effi ciency, metabolism and growth behavior of human mesenchymal stem cells (MSC) in vitro. Injury 2010; 41: 731-8.
8. LeGeros RZ. Properties of osteoconductive biomaterials: calcium phosphates. Clin Orthop Relat Res 2002: 81-98.
9. Campion CR, Chander C, Buckland T, et al. Increasing strut porosity in silicate-substituted calcium-phosphate bone graft substitutes enhances osteogenesis. J Biomed Mater Res B Appl Biomater 2011; 97: 245-54.
10. Wheeler DL, Jenis LG, Kovach ME, et al. Effi cacy of silicated calcium phosphate graft in posterolateral lumbar fusion in sheep. Spine J 2007; 7: 308-17. (Pubitemid 46667725)
11. Shepherd JH, Best SM. Calcium phosphate scaffolds for bone repair. JOM 2011; 63: 83-92.
12. Patel N, Brooks RA, Clarke MT, et al. In vivo assessment of hydroxyapatite and silicate-substituted hydroxyapatite granules using an ovine defect model. J Mater Sci Mater Med 2005; 16: 429-40. (Pubitemid 41217424)
13. Hing KA, Wilson LF, Buckland T. Comparative performance of three ceramic bone graft substitutes. Spine J 2007; 7: 475-90. (Pubitemid 47044790)
14. Peng CW, Yue WM, Poh SY, et al. Clinical and radiological outcomes of minimally invasive versus open transforaminal lumbar interbody fusion. Spine (Phila Pa 1976) 2009; 34: 1385-9.
15. Wu RH, Fraser JF, Hartl R. Minimal access versus open transforaminal lumbar interbody fusion: meta-analysis of fusion rates. Spine (Phila Pa 1976) 2010; 35: 2273-81.
16. Rouben D, Casnellie M, Ferguson M. Long-term durability of minimal invasive posterior transforaminal lumbar interbody fusion: a clinical and radiographic follow-up. J Spinal Disord Tech 2011; 24: 288-96.
17. Wong DA, Kumar A, Jatana S, et al. Neurologic impairment from ectopic bone in the lumbar canal: a potential complication of offlabel PLIF/TLIF use of bone morphogenetic protein-2 (BMP-2). Spine J 2008; 8: 1011-8.
18. Joseph V, Rampersaud YR. Heterotopic bone formation with the use of rhBMP-2 in posterior minimal access interbody fusion: a CT analysis. Spine (Phila Pa 1976) 2007; 32: 2885-90. (Pubitemid 351339361)
19. Simmonds MC, Brown JV, Heirs MK, et al. Safety and effectiveness of recombinant human bone morphogenetic protein-2 for spinal fusion: a meta-analysis of individual-participant data. Ann Intern Med 2013; 158: 877-89.
20. Sekhon L, Tomlinson A, Allen B, et al.
21. Immediate postoperative complications and radiological features of interbody fusion between INFUSE BMP and Actifuse: a randomized prospective trial. The Spine J 2009; 9: 32S-3S.
22. Aubin M, Drew J, Eskander M, et al. Clinical and radiological fusion rates following transforaminal lumbar interbody fusion (TLIF) with silicate-substituted calcium-phosphate bone graft substitute without ICBG for the surgical treatment of degenerative lumbar spine disease. Gp175. Spine Journal Meeting Abstracts 2010: 317.
23. Oliveira L, Marchi L, Coutinho E, et al. A radiographic assessment of the ability of the extreme lateral interbody fusion procedure to indirectly decompress the neural elements. Spine (Phila Pa 1976) 2010; 35: S331-7.
24. Pimenta L, Pesántez CFA, Oliveira L. Silicon matrix calcium phosphate as a bone substitute: early clinical and radiological results in a prospective study with 12-month follow-up. SAS J 2008; 2: 62-8.
25. Kozak JA, Heilman AE, O'Brien JP. Anterior lumbar fusion options. Technique and graft materials. Clin Orthop Relat Res 1994: 45-51. (Pubitemid 24085478)